Press release
GervanoRA Announced the Release of Opportunity Assessment Report Titled “Tardive Dyskinesia Drugs – Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2018”
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Tardive Dyskinesia Pipeline Drugs – Opportunity Assessments, Epidemiology Forecast, Market Dynamics, and Pipeline Analysis H2 2018.GervanoRA’s pipeline analysis and opportunity assessment report “Tardive Dyskinesia: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis, H2 2018” analyzed and assessed Tardive Dyskinesia pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Tardive Dyskinesia industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.
Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
• Unmet needs and Opportunities
• Epidemiology and Epidemiology forecast 2019 – 2025
• Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
• Patent Analysis of Pipeline Molecules
• Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
• Clinical Trials Summary
• Current and Future Competitive Landscape
• Key Company Profiles with SWOT Analysis
• Emerging Company Profiles with Opportunity Assessments
• Pipeline Drug Descriptions along with Development milestones (Past and Future)
• University Pipeline Molecules & In-Licensing/Out Licensing Opportunities
Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. METHODOLOGY
1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
1.4. ABOUT US: GERVANORA DATA SERVICES
2. EXECUTIVE SUMMARY
2.1. REPORT MAJOR FINDINGS
2.2. KEY EVENTS IN TARDIVE DYSKINESIA COMPETITIVE SPACE
3. DISEASE OVERVIEW
3.1. DISEASE DEFINITION & SYMPTOMS
3.1.1. CLINICAL MANIFESTATIONS
3.1.2. PATHOGENESIS
3.2. DISEASE CAUSE AND CLASSIFICATION
3.3. DISEASE DIAGNOSIS
3.4. TREATMENT ALGORITHM AND GUIDELINES
3.5. EPIDEMIOLOGY AND DISEASE BURDEN
3.6. EPIDEMIOLOGY FORECAST
3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
4. MARKET DYNAMICS
4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
4.2. PRICING AND REIMBURSEMENT
4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010
4.5. NEW DRUG APPROVALS (EX-US) SINCE 2010
4.6. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
5. PIPELINE ANALYSIS
5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
5.1.1. TARDIVE DYSKINESIA PHASE 3 MOLECULES
5.1.2. TARDIVE DYSKINESIA PHASE 2 MOLECULES
5.1.3. TARDIVE DYSKINESIA PHASE 1 MOLECULES
5.1.4. TARDIVE DYSKINESIA PRECLINICAL MOLECULES
5.1.5. TARDIVE DYSKINESIA EARLY R&D MOLECULES
5.1.6. TARDIVE DYSKINESIA INACTIVE AND DISCONTINUED MOLECULES
5.2. PIPELINE ANALYSIS BY GEOGRAPHY
5.2.1. UNMET NEEDS AND OPPORTUNITIES
5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
5.3.1. UNMET NEEDS AND OPPORTUNITIES
5.4. PIPELINE ANALYSIS BY DRUG CLASS
5.4.1. UNMET NEEDS AND OPPORTUNITIES
5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
5.5.1. UNMET NEEDS AND OPPORTUNITIES
5.6. PIPELINE MOLECULES BY UNIVERSITIES AND INSTITUTES
6 ESTIMATED APPROVAL TIMELINE
6.1.1. METHODOLOGY
6.1.2. ESTIMATED APPROVAL TIME LINES US & EX-US
7. TARDIVE DYSKINESIA CLINICAL TRIALS SUMMARY
7.1. TARDIVE DYSKINESIA PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS
7.1.1. KEY PHASE 3 RESULTS
7.1.2. KEY PHASE 2 RESULTS
7.2. ONGOING CLINICAL TRIALS SUMMARY
7.2.1 KEY PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
7.2.2 KEY PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
7.2.3. KEY PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
7.3. PLANNED CLINICAL TRIALS SUMMARY
7.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
7.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS SUMMARY
7.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS SUMMARY
7.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS SUMMARY
8. CURRENT AND FUTURE COMPETITIVE LANDSCAPE
8.1. COMPANIES
8.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
8.1.2. TOP 20 EMERGING COMPANIES IN THE TARDIVE DYSKINESIA AREA
8.3. UNIVERSITIES AND INSTITUTES – LICENSING OPPORTUNITIES
9. ABBREVIATIONS
LIST OF TABLES:
TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
TABLE 02: DISEASE EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
TABLE 03: MAJOR COLLABORATIVE AGREEMENTS IN THE TARDIVE DYSKINESIA AREA
TABLE 04: MAJOR LICENSING AGREEMENTS IN THE TARDIVE DYSKINESIA AREA
TABLE 05: MAJOR MERGERS AND ACQUISITIONS IN THE TARDIVE DYSKINESIA AREA
TABLE 06: MAJOR ALLIANCE AGREEMENTS IN THE TARDIVE DYSKINESIA AREA
TABLE 07: MAJOR FINANCING DEALS IN THE TARDIVE DYSKINESIA AREA
TABLE 08: MAJOR DEALS IN THE TARDIVE DYSKINESIA AREA RANKED BY DEAL AMOUNT
TABLE 09: US FDA APPROVED DRUGS SINCE 2010
TABLE 10: EX-US APPROVED DRUGS SINCE 2010
TABLE 11: PHASE 3 MOLECULES IN THE TARDIVE DYSKINESIA DRUG PIPELINE
TABLE 12: PHASE 2 MOLECULES IN THE TARDIVE DYSKINESIA DRUG PIPELINE
TABLE 13: PHASE 1 MOLECULES IN THE TARDIVE DYSKINESIA DRUG PIPELINE
TABLE 14: PRECLINICAL MOLECULES IN THE TARDIVE DYSKINESIA DRUG PIPELINE
TABLE 15: EARLY R&D MOLECULES IN THE TARDIVE DYSKINESIA DRUG PIPELINE
TABLE 16: INACTIVE AND DISCONTINUED MOLECULES IN THE TARDIVE DYSKINESIA DRUG PIPELINE
TABLE 17: TARDIVE DYSKINESIA PIPELINE MOLECULES BY ROUTE OF ADMINISTRATION
TABLE 18: TARDIVE DYSKINESIA PIPELINE MOLECULES OVERVIEW BY DRUG CLASS
TABLE 19: TARDIVE DYSKINESIA PIPELINE MOLECULES BY UNIVERSITIES
TABLE 20: TARDIVE DYSKINESIA PIPELINE MOLECULES BY INSTITUTES
TABLE 21: ESTIMATED APPROVAL TIME LINES OF PIPELINE MOLECULES
TABLE 22: KEY PHASE 3 ONGOING CLINICAL TRIALS
TABLE 23: KEY PHASE 2 ONGOING CLINICAL TRIALS
TABLE 24: KEY PHASE 1 ONGOING CLINICAL TRIALS
TABLE 25: PLANNED CLINICAL TRIALS FOR THE TARDIVE DYSKINESIA AREA
TABLE 26: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
TABLE 27: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
TABLE 28: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
TABLE 29: ESTABLISHED COMPANIES SCENARIO
TABLE 30: LIST OF EMERGING COMPANIES IN THE TARDIVE DYSKINESIA AREA
TABLE 31: COMPETITIVE OPPORTUNITIES, UNIVERSITIES
TABLE 32: COMPETITIVE OPPORTUNITIES, INSTITUTES
(Above mentioned tables are a few among the total 86 tables in the report)
LIST OF FIGURES:
FIGURE 01: KEY PIPELINE EVENTS, 2019-2029
FIGURE 02: TARDIVE DYSKINESIA EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
FIGURE 03: OVERALL DEALS ACTIVITY IN THE TARDIVE DYSKINESIA AREA
FIGURE 04: OVERALL DEAL FINANCING ACTIVITY V/S DEAL TYPE
FIGURE 05: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
FIGURE 06: TARDIVE DYSKINESIA DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
FIGURE 07: TARDIVE DYSKINESIA DRUG PIPELINE ANALYSIS BY GEOGRAPHY
FIGURE 08: TARDIVE DYSKINESIA DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
FIGURE 09: TARDIVE DYSKINESIA DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 10: TARDIVE DYSKINESIA DRUG PIPELINE ANALYSIS BY DRUG CLASS
FIGURE 11: TARDIVE DYSKINESIA PIPELINE MOLECULES DEVELOPED BY UNIVERSITIES AND INSTITUTES
FIGURE 12: ONGOING CLINICAL TRIALS SPLIT-UP BY HSD
FIGURE 13: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY HSD
FIGURE 14: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY MAJOR COMPANIES
FIGURE 15: COMPANY FINANCIAL INFORMATION
FIGURE 16: COMPANY SWOT ANALYSIS
(Above mentioned figures are a few among the total 52 figures in the report)
This report is available on promotional basis.
To view sample report: www.gervanora.com/request-for-sample-report/
Why Choose GervanoRA??
GervanoRA is working dedicatedly for healthcare (Pharma & Medical Device) domain to empower our client’s business by assisting them in decision making with our wealthiness of database, expertise in analytics, and domain experts.
Vast & Tailor-made Database: GervanoRA utilizes its in-built rich database of pharmaceutical sector and Medical device sector to help our clients with their bespoke requirements. We have databases of Pharma Pipeline Drugs, Pharma News, Pharma Deals and Pipeline Medical Devices, Medical Device News and Medical Device Deal.
Coverage: We cover almost all major countries on the globe by providing Pharma & Medical device pipeline insights along with epidemiology, epidemiology forecast, Patent analysis, Insights on clinical trials and emerging opportunities. Using our database analytics, we are cracking the future numbers to assess market opportunities in healthcare domain.
Resources to meet the Goals: We have great number of experts, Analysts, Senior Researchers and Researchers to take care of our dynamic day to day process, like building database, updating the database, optimizing primary inputs, using internal tools analytics, Conducting KOL Interviews and Gathering field intelligence through paid surveys in all healthcare markets.
About GervanoRA:
GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports and consulting services, based in Goa, India. GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.
At GervanoRA Data Services, we are playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations (KOLs) to garner valuable key insights.
To assist our global clients to attain their segment and sub segment specific goals, we are enlightening them on domain specific live updates through our GervanoRA 360 Degree PharmMedTech Monthly Bulletin (Monthly Report) which serve our clients with bespoke requirements without missing any live update for the particular month, as we know how valuable it is to be stayed updated with day to day dynamic industry sectors.
GervanoRA Data Services LLP
Goa IT Innovation Centre,
Goa Chamber of Commerce and Industry Bldg, 2nd Floor, S-2 Block,
Opp: Hyundai Showroom, Verna, South Goa,
Goa INDIA 403722
Email: sales@gervanora.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GervanoRA Announced the Release of Opportunity Assessment Report Titled “Tardive Dyskinesia Drugs – Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2018” here
News-ID: 1737583 • Views: …
More Releases from GervanoRA Data Services
GervanoRA Announces Financial Results of 2022-2023
GervanoRA Data Services (GDS) is an AI based emerging healthcare consulting company based in Goa India with 12 global offices spread across the world, announced today that it has released the financial results of 2022-2023 and with our tremendous team efforts, we achieved around 18% growth in earnings, 28% increments in developmental activities and 30% growth in monetary hold compared to the previous financial year 2021-2022. We are providing AI…

GervanoRA Announced the Release of Market Dynamics and Opportunity Assessment Re …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Hemophilia A - Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis H2 2019 Report.
GervanoRA’s pipeline analysis and opportunity assessment report “Hemophilia A: Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis, H2 2019” analyzed and assessed Hemophilia A pipeline molecules for the opportunities in the…

GervanoRA Announced the Release of Market Dynamics and Opportunity Assessment Re …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Schizophrenia - Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis H2 2019 Report.
GervanoRA’s pipeline analysis and opportunity assessment report “Schizophrenia: Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis, H2 2019” analyzed and assessed Schizophrenia pipeline molecules for the opportunities in the competitive space by…
GervanoRA Announced the Release of Market Dynamics and Opportunity Assessment Re …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Beta-Thalassemia Pipeline Drugs - Pipeline Analysis, Opportunity Assessments, Epidemiology Forecast, Market Dynamics, H2 2019 .
GervanoRA’s pipeline analysis and opportunity assessment report “Beta-Thalassemia: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis, H2 2019” analyzed and assessed Beta-Thalassemia pipeline molecules for the opportunities in the…
More Releases for TARDIVE
Tardive Dyskinesia Treatment Market Analysis By Drug Class & Distribution Channe …
The Tardive Dyskinesia Treatment Market is expected to Reach a CAGR of 4% during the forecast period (2024-2031).
Tardive Dyskinesia Treatment Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it…
Tardive Dyskinesia Market Report and Forecast 2024-2032
The tardive dyskinesia market size is anticipated to grow at a CAGR of 3.2 % during the forecast period of 2024-2032, driven by growing awareness about the importance of monitoring patients on long-term antipsychotic therapy for early signs of tardive dyskinesia in the major markets.
Tardive Dyskinesia: Introduction
Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive body movements. It primarily affects the face, causing grimacing, blinking, or lip-smacking, but can…
Global Tardive Dyskinesia (TD) Treatment Market - Opportunities & Forecasts, 202 …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global tardive dyskinesia (td) treatment market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was able to…
Tardive Dyskinesia Drugs Market Competitor Landscape, Opportunity Analysis, Grow …
Tardive neurological disorder (TD) may be a kind of dyskinesia that's tough to treat. it's a nerve disorder characterised by involuntary movements like jaw, lips, and tongue, thought-about as grimacing, protrusive the tongue out, and lip smack. another symptoms square measure a private experiencing involuntary movement of the lower and higher extremities and additionally respiratory choking.
Get HOLISTIC Request Sample Copy:https://www.coherentmarketinsights.com/insight/request-sample/218
consistent with Center for Drug analysis and analysis, dyskinesia will…
Tardive Dyskinesia (TD) Treatment Drugs Market Size, Share, Development by 2024
LP INFORMATION offers a latest published report on Tardive Dyskinesia (TD) Treatment Drugs Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Tardive Dyskinesia (TD) Treatment Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$…
Antioxidants May Aid in the Treatment of Tardive Dyskinesia
Memphis, TN (May 9, 2019) – Today, The Primary Care Companion for CNS Disorders published a case report on the use of antioxidants in the treatment of tardive dyskinesia. While new pharmacologic discoveries have occurred in the area of movement disorders, their use comes with a large price tag. Thus, for mild cases, clinicians may want to seek out more cost-effective options. Antioxidants may serve a role in the prevention…